What is the 13F Pro Quality Score for NTLA?

13F Pro ranks Intellia Therapeutics, Inc. (NTLA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NTLA's current score at https://13fpro.ai/research/NTLA (free sign-up required for the full ranking).

Which hedge funds own the most NTLA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of NTLA include ARK Investment Management, BlackRock,, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/NTLA as soon as new 13F filings post.

Where does 13F Pro source NTLA data?

All Intellia Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Intellia Therapeutics, Inc. files with the SEC under CIK 1652130. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NTLA in?

Intellia Therapeutics, Inc. (NTLA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NTLA research updated on 13F Pro?

NTLA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Intellia Therapeutics, Inc.(NTLA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1652130 NTLA stock profile & AI dashboard →

13F Pro Quality Score

24.5/100

Rank #2,579 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

95.0/100

Profitability

3.1/100

Balance Sheet

3.5/100

Earnings Quality

30.0/100

Free Cash Flow

2.6/100

Institutional Flow

7.6/100

Revenue Scale

12.7/100

Dilution Risk

2.8/100

NTLA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Intellia Therapeutics, Inc. (NTLA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NTLA at 24.5/100 on a 32-signal composite quality model, placing it at rank #2,579 of 2,879 stocks — the bottom half of the AI-ranked universe. NTLA scores in the top quartile across revenue growth (95.0). Areas of concern include free cash flow (2.6) and profitability (3.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Intellia Therapeutics, Inc. reports quarterly revenue of $15.0M, net income of $-96.2M, free cash flow of $-117.4M. Top institutional holders of NTLA by reported 13-F value include ARK Investment Management, BlackRock,, STATE STREET, based on the most recent SEC filings. NTLA trades on the Nasdaq exchange and files with the SEC under CIK 1652130. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NTLA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Intellia Therapeutics, Inc. directly from SEC EDGAR. Intellia Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 11 and 33 since 2021, currently 24.5 — an improving long-term trajectory across 25 quarterly and live scoring snapshots.

✦

Fun facts about Intellia Therapeutics, Inc.

Quirks, history, and lore behind NTLA — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biotechnology company · clinical-stage · listed on Nasdaq · headquartered in Cambridge, Massachusetts.
2
The Numbers
Revenues are minimal — this is a pre-commercial biotech burning through cash on R&D, with a market cap that has swung wildly between roughly $1 billion and $8 billion depending on trial news.
3
The History
Founded in 2014, it was spun out of the pioneering genome-editing research of Caribou Biosciences co-founder Jennifer Doudna's scientific circle, right as the CRISPR gold rush began.
4
The Secret
Its ambition isn't just treating disease — it wants to permanently edit faulty genes inside a living patient's body, making a one-time fix instead of a lifetime of pills.
5
The Lore
It achieved a landmark by dosing patients with an in vivo CRISPR therapy directly into the liver, a first-of-its-kind milestone that sent the whole gene-editing sector buzzing.
6
The Giveaway
Its name blends "intelligence" with the suffix of the revolutionary CRISPR-Cas9 gene-editing tool it was built to wield — the cleverest branding in genomic medicine.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$15.0M

Net Income

Q1 2026

$-96.2M

Free Cash Flow

Q1 2026

$-117.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+59.6% YoY

$57.9MFY 2024

FY21 $33.1MFY22 $52.1MFY23 $36.3MFY24 $57.9M

Net Income

-7.9% YoY

$-519.0MFY 2024

FY21 $-267.9MFY22 $-474.2MFY23 $-481.2MFY24 $-519.0M

Operating Income

-3.7% YoY

$-534.3MFY 2024

FY21 $-267.9MFY22 $-458.2MFY23 $-515.3MFY24 $-534.3M

EPS (Diluted)

+3.1% YoY

$-5.25FY 2024

FY21 $-3.78FY22 $-6.16FY23 $-5.42FY24 $-5.25

Total Assets

-8.5% YoY

$1.19BFY 2024

FY21 $1.29BFY22 $1.52BFY23 $1.30BFY24 $1.19B

Op. Cash Flow

+11.5% YoY

$-348.9MFY 2024

FY21 $-225.0MFY22 $-333.3MFY23 $-394.1MFY24 $-348.9M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$57.9M +59.6%	$36.3M -30.4%	$52.1M +57.7%	$33.1M -43.0%	$58.0M +34.5%	$43.1M
Net Income	$-519.0M -7.9%	$-481.2M -1.5%	$-474.2M -77.0%	$-267.9M -99.6%	$-134.2M +71.7%	$-474.2M
Operating Income	$-534.3M -3.7%	$-515.3M -12.5%	$-458.2M -71.1%	$-267.9M -96.1%	$-136.6M -28.4%	$-106.4M
EPS (Diluted)	$-5.25 +3.1%	$-5.42 +12.0%	$-6.16 -63.0%	$-3.78 -57.5%	$-2.40	—
Total Assets	$1.19B -8.5%	$1.30B -14.4%	$1.52B +17.4%	$1.29B +91.4%	$676.3M +102.3%	$334.3M
Operating Cash Flow	$-348.9M +11.5%	$-394.1M -18.2%	$-333.3M -48.1%	$-225.0M -350.9%	$-49.9M +51.7%	$-103.2M

AI Insight: NTLA Financial Trends

Losses are narrowing steadily — operating loss compressed from -$139M in Q2 2024 to -$101M in Q1 2026 — but equity erosion continues unabated.

• Operating loss improved from -$139M in Q2 2024 to -$101M in Q1 2026, a ~$38M reduction over six quarters.

• Revenue grew from $7M in Q2 2024 to $23M in Q4 2025, though Q1 2026 dipped back to $15M, signaling quarterly volatility.

• Equity has declined every quarter from $971M in Q2 2024 to $621M in Q1 2026, a cumulative erosion of $350M.

• Operating cash outflow spiked to -$149M in Q1 2025 before improving to -$69M in Q4 2025, then re-widened to -$117M in Q1 2026.

⚠ Equity runway is shrinking fast — at the current burn rate, the $621M equity base could become critically thin within a few quarters.

⚠ Q1 2026 operating cash outflow re-accelerated to -$117M after four quarters of improvement — a potential trend reversal to monitor.

⚠ No debt reported across all periods; watch for any debt issuance as equity depletes, which would introduce leverage risk.

AI Insight: NTLA Ratio Trends

Intellia's return metrics remain deeply negative, with ROIC deteriorating to -64.8% in Q1 2026 after a brief mid-2025 improvement.

• ROIC improved modestly from -62.6% in Q4 2024 to -58.8% in Q4 2025, but reversed sharply to -64.8% in Q1 2026.

• ROA tightened from -49.3% in Q2 2024 to -43.8% by Q3 2025, then deteriorated to -50.7% in Q1 2026.

• OpMargin, NPM, and D/E are unavailable across all reported periods, limiting profitability and leverage analysis.

⚠ ROE worsened to -62.0% in Q1 2026 from -54.1% in Q3 2025 — the steepest single-quarter deterioration in the dataset.

⚠ TTM ROIC of -67.8% is worse than any individual quarter shown, signaling cumulative cash burn acceleration.

Get alerted when NTLA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Intellia Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NTLA

ARK Investment Management LLC
$186.0M14,509,247 sh
BlackRock, Inc.
$155.8M12,155,806 sh
STATE STREET CORP
$88.7M6,922,676 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$79.8M6,223,325 sh
D. E. Shaw & Co., Inc.
$73.4M5,728,177 sh
VANGUARD CAPITAL MANAGEMENT LLC
$65.2M5,084,105 sh
TWO SIGMA INVESTMENTS, LP
$60.3M4,705,901 sh
REGENERON PHARMACEUTICALS, INC.
$47.5M3,702,995 sh
GEODE CAPITAL MANAGEMENT, LLC
$36.6M2,851,472 sh
UBS Group AG
$34.5M2,689,486 sh

Fund	Value	Shares
ARK Investment Management LLC	$186.0M	14,509,247
BlackRock, Inc.	$155.8M	12,155,806
STATE STREET CORP	$88.7M	6,922,676
VANGUARD PORTFOLIO MANAGEMENT LLC	$79.8M	6,223,325
D. E. Shaw & Co., Inc.	$73.4M	5,728,177
VANGUARD CAPITAL MANAGEMENT LLC	$65.2M	5,084,105
TWO SIGMA INVESTMENTS, LP	$60.3M	4,705,901
REGENERON PHARMACEUTICALS, INC.	$47.5M	3,702,995
GEODE CAPITAL MANAGEMENT, LLC	$36.6M	2,851,472
UBS Group AG	$34.5M	2,689,486

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NTLA on your watchlist

Track score changes the day Intellia Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NTLA a good stock to buy?

13F Pro's AI-powered analysis of Intellia Therapeutics, Inc. (NTLA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NTLA are available on the NTLA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NTLA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NTLA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Intellia Therapeutics, Inc.'s investment landscape.